JP2020520963A - 抑うつ障害の処置 - Google Patents

抑うつ障害の処置 Download PDF

Info

Publication number
JP2020520963A
JP2020520963A JP2019564822A JP2019564822A JP2020520963A JP 2020520963 A JP2020520963 A JP 2020520963A JP 2019564822 A JP2019564822 A JP 2019564822A JP 2019564822 A JP2019564822 A JP 2019564822A JP 2020520963 A JP2020520963 A JP 2020520963A
Authority
JP
Japan
Prior art keywords
gaboxadol
pharmaceutical composition
parenteral administration
pharmaceutically acceptable
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520963A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2020520963A publication Critical patent/JP2020520963A/ja
Publication of JP2020520963A5 publication Critical patent/JP2020520963A5/ja
Priority to JP2023009149A priority Critical patent/JP2023061957A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019564822A 2017-05-24 2018-05-22 抑うつ障害の処置 Pending JP2020520963A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023009149A JP2023061957A (ja) 2017-05-24 2023-01-25 抑うつ障害の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762510481P 2017-05-24 2017-05-24
US62/510,481 2017-05-24
US15/933,673 US20180338959A1 (en) 2017-05-24 2018-03-23 Treatment of depressive disorders
US15/933,673 2018-03-23
PCT/US2018/033848 WO2018217718A1 (en) 2017-05-24 2018-05-22 Treatment of depressive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009149A Division JP2023061957A (ja) 2017-05-24 2023-01-25 抑うつ障害の処置

Publications (2)

Publication Number Publication Date
JP2020520963A true JP2020520963A (ja) 2020-07-16
JP2020520963A5 JP2020520963A5 (enExample) 2021-07-26

Family

ID=64395877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564822A Pending JP2020520963A (ja) 2017-05-24 2018-05-22 抑うつ障害の処置
JP2023009149A Withdrawn JP2023061957A (ja) 2017-05-24 2023-01-25 抑うつ障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023009149A Withdrawn JP2023061957A (ja) 2017-05-24 2023-01-25 抑うつ障害の処置

Country Status (10)

Country Link
US (4) US20180338959A1 (enExample)
EP (2) EP3630065A4 (enExample)
JP (2) JP2020520963A (enExample)
KR (1) KR20200018485A (enExample)
CN (2) CN110996910A (enExample)
AU (1) AU2018272819A1 (enExample)
CA (1) CA3064299A1 (enExample)
IL (1) IL270781A (enExample)
MX (1) MX393452B (enExample)
WO (1) WO2018217718A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
BR112021009944A2 (pt) 2018-11-21 2021-08-17 Certego Therapeutics Inc. gaboxadol para reduzir risco de suicídio e alívio rápido de depressão
AU2020223284A1 (en) 2019-02-17 2021-09-16 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
KR102085938B1 (ko) * 2019-11-04 2020-03-06 한국메탈실리콘 주식회사 실리콘 복합체 제조방법
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015049A1 (en) * 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
EP2145620A3 (en) * 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AU2005229493A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US10628156B2 (en) * 2013-07-09 2020-04-21 Texas Instruments Incorporated Vector SIMD VLIW data path architecture
RS62006B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
CA3146737A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015049A1 (en) * 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEURON, vol. 59, JPN6022006263, 2008, pages 207 - 213, ISSN: 0005021728 *

Also Published As

Publication number Publication date
AU2018272819A1 (en) 2019-12-05
CN115105499A (zh) 2022-09-27
CN110996910A (zh) 2020-04-10
EP3939587A1 (en) 2022-01-19
EP3630065A4 (en) 2021-03-24
US20190117633A1 (en) 2019-04-25
IL270781A (en) 2020-01-30
CA3064299A1 (en) 2019-11-29
US20200179351A1 (en) 2020-06-11
JP2023061957A (ja) 2023-05-02
MX2019014024A (es) 2020-02-17
US20180338959A1 (en) 2018-11-29
KR20200018485A (ko) 2020-02-19
US20210379028A1 (en) 2021-12-09
MX393452B (es) 2025-03-24
WO2018217718A1 (en) 2018-11-29
EP3630065A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
JP2023061957A (ja) 抑うつ障害の処置
JP6328855B2 (ja) 即効型インスリン組成物
JP2023126947A (ja) てんかん性障害の処置のための方法および組成物
JP6353577B2 (ja) 組み合わせ組成物
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
AU2018217271A1 (en) Stable parenteral DNJ compositions
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
BRPI0613731A2 (pt) composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
AU2020275208B2 (en) Formulation of delgocitinib in the form of a cream
CN107961215B (zh) 一种左西替利嗪注射剂
HK40027257A (en) Treatment of depressive disorders
KR20120089444A (ko) 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
ES2701444T3 (es) Usos de bremelanotida en una terapia para la disfunción sexual femenina
WO2025120013A1 (en) Compositions and methods for treating depression disorders
WO2025155754A1 (en) Intranasal olanzapine formulations and methods of their use
WO2020025986A1 (en) Injectable combination of diclofenac sodium and thiocolchicoside
ES2350670B1 (es) Composicion veterinaria de ketoprofeno
HK1214956B (zh) 稳定的肠胃外dnj组合物
JP2013227319A (ja) 鼻内送達用シアノコバラミン低粘度水性製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210521

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328